AlphAIalphai — Financial news for AI agents
insurancebusinessmag.comJUL 285 min read$BRO

Brown & Brown posts $1.7 billion Q2 revenue but organic growth stalls

Brown & Brown reported Q2 2026 revenue of $1.7 billion, up 30.4% y/y, but organic revenue fell 0.7% for the second straight quarter. Net income attributable was $288 million (+24.7%); diluted EPS was $0.84 (+7.7%). Adjusted EBITDAC was $598 million, with margin down to 35.7%. Costs rose from acquisitions and interest expense tied to the RSC Topco/Accession deal.

Original reporting
insurancebusinessmag.com
Published Jul 28, 2026, 8:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 28, 2026, 10:03 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Brown & Brown posts $1.7 billion Q2 revenue but organic growth stalls — source image
Source · insurancebusinessmag.com
Decision brief

The 30-second read

$BRONeutralMed
01

Why it matters

The key trade signal is the divergence between strong reported growth and weak organic growth, alongside margin compression from a higher cost base and doubled interest expense tied to acquisition debt.

02

Market read

Q2 print provides fresh operating detail: organic revenue -0.7% for the second straight quarter, adjusted EBITDAC margin down, and higher interest expense from acquisition debt.

03

What to watch

The article notes an organic revenue reconciliation litigation-related impact adjustment and timing issues (~$10M) in specialty distribution; these could overstate underlying demand weakness if they reverse.

Relevance 7/10Novelty 6/10Timing: ahead of the second-half 2026 outlook window, after Q2 results

Background

Brown & Brown’s growth mix is increasingly acquisition-driven, with Accession integration costs cited as a headwind to organic revenue.

Company-level read

Ticker impact

$BRONeutralMedium confidence
Context

Brown & Brown reported Q2 2026 total revenue of $1.7B but organic revenue fell 0.7%, citing Accession integration costs and margin compression.

Expected impact

Choppy trading risk, with downside bias if investors focus on organic decline and margin contraction rather than acquisition-driven top-line growth.

Evidence & confidence

The article provides concrete operating drivers: organic revenue -0.7% (second straight quarter), adjusted EBITDAC margin down to 35.7% from 36.7%, compensation up, and interest expense doubling due to debt for the RSC Topco acquisition (Accession).

Market effects

Sector

Highlights ongoing pressure from commercial property rate dynamics and catastrophe property rate declines, relevant to insurance distribution and brokerage demand.

Regional

No specific regional breakdown provided; impact framed as broader commercial property rate environment.

Global

Primarily US commercial property and E&S casualty rate commentary; limited direct global linkage in the text.

Counterpoint

What could challenge this read

Investors may look through organic softness as temporary integration drag, focusing instead on retail segment growth (organic +1.5%) and continued earnings growth.

Key entities

  • public_company
    Brown & Brown, Inc.

    Insurance brokerage/distribution firm reporting Q2 2026 results with stalled organic growth and margin compression.

  • acquisition_integration
    Accession (RSC Topco, Inc. acquisition)

    Integration costs are cited as weighing on organic revenue; debt taken to fund the acquisition increased interest expense.

  • market_driver
    E&S casualty rates

    Company expects E&S casualty rates to keep rising given the legal environment, with admitted line rate changes broadly similar to Q2 in 2H 2026.

Read at source← All news

Related articles

JUL 28
$BROMed

Why Are Brown & Brown (BRO) Shares Soaring Today

Brown & Brown (NYSE: BRO) shares rose about 5% after the company reported Q2 results. Revenue increased 30.4% year over year to $1.68B, slightly below analysts’ $1.72B estimate. Adjusted EPS was $1.07, in line with expectations, driving investor focus on strong growth despite the revenue miss.

financialcontent.com4 min
JUL 28
$BROMed

Brown & Brown Q2 Earnings Call Highlights

Brown & Brown (NYSE:BRO) discussed Q2 results on its earnings call. CFO Andy Watts said Retail revenue rose 35.9% mainly from acquisitions, while Retail organic growth was pressured by a pharmacy consulting business and a litigation-related organic revenue adjustment. Specialty Distribution total revenue rose 28.1% on Accession, with EBITDAC margin down to 42.7%. BRO expects H2 Retail organic growth excluding contingents of 1.5% to 2.5% and Specialty 2% to 4%, and reaffirmed $30M-$40M integratio

yahoo.com7 min
JUL 27
$BROMedAI 8/10

Brown & Brown, Inc. announces second quarter 2026 results, including total revenues of $1.7 billion, an increase of 30.4%; Organic Revenue decrease of 0.7%; growth of Organic Revenue with Contingents

Brown & Brown, Inc. (NYSE:BRO) reported unaudited Q2 2026 results. Total revenues rose to $1.7 billion, up 30.4% year over year, while organic revenue fell 0.7%. Net income attributable to the company increased to $288 million, and diluted EPS was $0.84. For six months, revenues were $3.6 billion, up 33.0%.

thestarphoenix.com6 min
JUL 27
$BROMedAI 8/10

BROWN & BROWN, INC. (BRO): Results of Operations and Financial Condition

BROWN & BROWN, INC. (BRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bro-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Brown & Brown, Inc. announces second quarter 2026 results, including total revenues of $1.7 billion, an increase of 30.4%; Organic Revenue decrease of 0.7%; growth of Organic Revenue with Contingents of 0.7%; diluted net incom

SEC EDGAR 8-K6 min
JUL 6
$BROMedAI 8/10

Why Brown & Brown (BRO) Stock Is Down Today

Brown & Brown (NYSE: BRO) shares fell about 2.6% after Morgan Stanley downgraded the stock to Underweight from Equalweight and cut its price target, citing concerns over organic growth reset, a softer pricing cycle, Florida exposure, and tougher competition and hiring. Barclays raised its target to $76 from $72. Shares traded near $68.04.

financialcontent.com5 min